Información del artículo
Las glinidas representan una nueva familia de secretadores de insulina, químicamente heterogénea, caracterizados por un inicio de acción rápido y de corta duración. La repaglinida posee un efecto hipoglucemiante superponible al de las sulfonilureas convencionales. Algunos estudios indican un descenso en el riesgo de hipoglucemias, sobre todo nocturnas, y en el caso de omisión de una comida principal. Este fármaco parece especialmente útil en estadios iniciales de la diabetes tipo 2 y en combinación con metformina. Puede emplearse en pacientes con insuficiencia renal moderada y está contraindicada en caso de insuficiencia hepática grave. La nateglinida presenta una menor duración de acción y un peor control de la hemoglobina glucosilada que la repaglinida. Algunos estudios experimentales sugieren que las glinidas pueden preservar mejor que las sulfonilureas la función de la célula beta pancreática y que el mejor control de las excursiones glucémicas posprandiales podría tener un efecto beneficioso en la reducción del riesgo cardiovascular de estos pacientes.
Palabras clave:
Repaglinida
Nateglinida
Diabetes mellitus tipo 2
Glucemia posprandial
Uso terapéutico
Glinides are a new, chemically heterogeneous class of insulin-secreting agents characterized by rapid onset and short duration of action. Repaglinide has an equivalent hypoglycemic effect to conventional sulfonylureas. Several studies have reported a decreased risk of hypoglycemias, particularly nocturnal hypoglycemic episodes or those occurring after a main meal has been missed. This drug seems to be particularly useful in the early stages of type 2 diabetes or in combination with metformin. Repaglinide can be used in patients with moderate renal insufficiency, but is contraindicated in severe hepatic dysfunction. Nateglinide has a shorter duration of action and is less effective in HbA1c control than repaglinide. Several experimental studies have suggested that glinides could be more effective in preserving beta-cell function than sulfonylureas, and that improvement of postprandial glucose levels could exert a protective cardiovascular effect.
Key words:
Repaglinide
Nateglinide
Type 2 diabetes mellitus
Postprandial glycemia
Therapeutic use
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.F. McLeod.
Clinical pharmacokinetics of nateglinide. A rapidly-absorved, short-acting insulinotropic agent.
Clin Pharmacokinet, 4 (2004), pp. 97-120
[2.]
C.R. Culy, B. Jarvis.
Repaglinide. A review of its therapeutic use in type 2 diabetes mellitus.
Drugs, 61 (2001), pp. 1625-1660
[3.]
T.B. Bidstrup, I. Bjornsdottir, U.G. Sidelman, M.S. Thomsen, K.T. Hansen.
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
Br J Clin Pharmacol, 56 (2003), pp. 305-314
[4.]
M. Niemi, J.T. Backman, M. Neuvonen, P.J. Neuvonen.
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Diabetologia, 46 (2003), pp. 347-351
[5.]
L.I. Kajosaari, J.T. Backman, M. Neuvonen, J. Laitila, P.J. Neuvonen.
Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.
Br J Clin Pharmacol, 58 (2004), pp. 390-396
[6.]
A.J. Scheen.
Drug interactions of clinical importance with antihyperglycaemic agents. An update.
Drug Safety, 28 (2005), pp. 601-631
[7.]
L.S. Cozma, S.D. Luzio, G.J. Dunseath, P.M. Underwood, D.R. Owens.
Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.
Diabetes Care, 28 (2005), pp. 1001-1007
[8.]
J.F. Blickle.
Meglitinide analogues: a review of clinical data focused on recent trials.
Diabetes Metab, 32 (2006), pp. 113-120
[9.]
J. Rosenstock, D.R. Hassman, R.D. Madder, S.A. Brazinsky, J. Farrell, N. Khutoryansky, Repaglinide versus Nateglinide Comparison Study Group, et al.
Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.
Diabetes Care, 27 (2004), pp. 1265-1270
[10.]
P. Damsbo, P.H. Andersen, S. Lund, N. Porksen.
Improved glycaemic control with repaglinide in NIDDM with 3 times daily meal related dosing [abstract].
Diabetes, 46 (1997), pp. 34A
[11.]
R. Landgraf, H.J.G. Bilo, P.G. Muller.
A comparison of repaglinide and g libenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas.
Eur J Clin Pharmacol, 55 (1999), pp. 165-171
[12.]
B.H. Wolffenbuttel, R. Landgraf.
A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.
Diabetes Care, 22 (1999), pp. 463-467
[13.]
T. Marbury, W.C. Huang, P. Strange, H. Lebovitz.
Repaglinide versus glyburide: a one-year comparison trial.
Diabetes Res Clin Pract, 43 (1999), pp. 155-166
[14.]
E.J. Abbink, P.S. Van der Wal, C.G. Sweep, P. Smits, C.J. Tack.
Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation.
Diabetes Metab Res Rev, 20 (2004), pp. 466-471
[15.]
P.A. Hollander, S.L. Schwartz, M.R. Gatlin, S.J. Haas, H. Zheng, J.E. Foley, et al.
Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes.
Diabetes Care, 24 (2001), pp. 983-988
[16.]
M.R. Rizzo, M. Barbieri, R. Grella, N. Passariello, M. Barone, G. Paolisso.
Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study.
Diabetes Metab, 30 (2004), pp. 81-89
[17.]
G. Derosa, A. Mugellini, L. Ciccarelli, G. Crescenzi, R. Fogari.
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors.
Clin Ther, 25 (2003), pp. 472-484
[18.]
L.S. Cozma, S.D. Luzio, G.J. Dunseath, K.W. Langendorg, T. Pieber, D.R. Owens.
Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal.
Diabetes Care, 25 (2002), pp. 1271-1276
[19.]
S. Madsbad, B. Kilhovd, I. Lager, P. Mustajoki, A. Dejgaard, Scandinavian Repaglinide Group.
Comparison between repaglinide and glipizide in type 2 diabetes mellitus: a 1-year multicentre study.
Diabetic Med, 18 (2001), pp. 391-401
[20.]
S. Miwa, H. Watada, C. Ohmura, Y. Tanaka, R. Kawamori.
Efficacy and safety of once daily gliclazide (20 mg/day) compared with nateglinide.
Endocr J, 51 (2004), pp. 393-398
[21.]
P. Raskin, L. Klaff, S. McGill, S.A. South, P. Hollander, N. Khutoryansky, et al.
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Diabetes Care, 26 (2003), pp. 2063-2068
[22.]
N.J. Furlong, S.A. Hulme, S.V. O’Brien, K.J. Hardy.
Comparison of repaglinide versus gliclazide combined with nocturnal NPH insulin in patients with type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
Diabet Med, 20 (2003), pp. 935-941
[23.]
N.J. Furlong, S.A. Hulme, S.V. O’Brien, K.J. Hardy.
Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy.
Diabetes Care, 25 (2002), pp. 1685-1690
[24.]
A. Panelo, J.R. Wing, AGEE-1272 Study Group.
Repaglinide/bedtime NPH insulin is comparable to twice-daily NPH insulin.
Diabetes Care, 28 (2005), pp. 1789-1790
[25.]
M. Hanefeld, F. Schaper.
Prandial hiperglycemia: is it important to track and treat?.
Curr Diabet Reports, 5 (2005), pp. 333-339
[26.]
M. Hanefeld, J.L. Chiasson, C. Koehler, E. Henkel, F. Schaper, T. Temelkova-Kurktschiev.
Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.
Stroke, 35 (2004), pp. 1073-1078
[27.]
K. Esposito, D. Giugliano, F. Nappo, R. Marfella, For the Campanian Postprandial Hyperglycemia Study Group.
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.
Circulation, 110 (2004), pp. 214-219
[28.]
M.R. Rizzo, M. Barbieri, R. Grella, N. Passariello, G. Paolisso.
Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
Diabetes Metab, 31 (2005), pp. 255-260
[29.]
D. Manzella, R. Grella, A.M. Abbatecola, G. Paolisso.
Repaglinide administration improves brachial reactivity in type 2 diabetic patients.
Diabetes Care, 28 (2005), pp. 366-371
[30.]
N. Tentolouris, E. Boutati, N. Karambakalis, D. Perrea, A.D. Tselepis, C. Tsoukala, et al.
Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Nutr Metab Cardiovasc Dis, 15 (2005), pp. 6-12
[31.]
V. Hatorp, W.C. Huang, P. Strange.
Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes.
J Clin Endocrinol Metab, 84 (1999), pp. 1475-1478
[32.]
G. Papa, V. Fedele, M.R. Rizzo, M. Fioravanti, C. Leotta, S.B. Solerte, et al.
Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial.
Diabetes Care, 29 (2006), pp. 1918-1920
[33.]
A.M. Abbatecola, M.R. Rizzo, M. Barbieri, R. Grella, A. Arciello, M.T. Laieta, et al.
Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics.
Neurology, 67 (2006), pp. 235-240
[34.]
C. Hasslacher, Multinational Repaglinide Renal Study Group.
Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function.
Diabetes Care, 26 (2003), pp. 886-891
[35.]
M. Hanefeld, S. Fischer, U. Julius, J. Schulze, U. Schwanebeck, H. Schmechel, et al.
Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.
Diabetologia, 39 (1996), pp. 1577-1583
[36.]
M.L. Sievers, P.H. Bennett, R.G. Nelson.
Effect of glycemia on mortality in Pima Indians with type 2 diabetes.
Diabetes, 48 (1999), pp. 896-902
[37.]
J. Kuusisto, L. Mykkanen, K. Pyorala, M. Laakso.
NIDDM and its meta-bolic control predict coronary heart disease in elderly subjects.
Diabetes, 43 (1994), pp. 960-967
[38.]
E. Bonora, M. Muggeo.
Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence.
Diabetologia, 44 (2001), pp. 2107-2114
[39.]
T.S. Temelkova-Kurktschiev, C. Koehler, E. Henkel, W. Leonhardt, K. Fuecker, M. Hanefeld.
Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c.
Diabetes Care, 23 (2000), pp. 1830-1834
[40.]
P.H. Beks, A.J. Mackaay, H. de Vries, J.N. de Needing, L.M. Bouter, R.J. Heine.
Carotid artery stenosis is related to blood glucose level in an elderly Caucasian population: the Hoorn Study.
Diabetologia, 40 (1997), pp. 290-298
[41.]
M. Shichiri, H. Kishikawa, Y. Ohkubo, N. Wake.
Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.
Diabetes Care, 23 (2000), pp. B21-B29
[42.]
D.M. Nathan, J.B. Buse, M.B. Davidson, R.J. Heine, R.R. Holman, R. Sherwin, et al.
Management of Hyperglycemia in Type 2 Diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
Diabetes Care, 29 (2006), pp. 1963-1972
[43.]
American Diabetes Association.
Standards of Medical Care in Diabetes–2007.
Diabetes Care, 30 (2007), pp. S4-S34
[44.]
R. Moses, R. Slobodniuk, S. Boyages, S. Colagiuri, W. Kidson, J. Carter, et al.
Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
Diabetes Care, 22 (1999), pp. 119-124
[45.]
P. Raskin, L. Jovanovic, S. Berger, S. Schwartz, V. Woo, R. Ratner.
Repaglinide/troglitazone combination therapy: improved glycemic control in type 2 diabetes.
Diabet Care, 23 (2000), pp. 979-983
[46.]
L. Jovanovic, R. Jain, S. Greco, P. Hale, N. Khutoryansky, O. Santiago.
Repaglinide/pioglitazone combination therapy of type 2 diabetes.
Diabetes, 50 (2001), pp. A439
[47.]
P. Raskin, J. McGill, M.F. Saad, J.M. Cappleman, W. Kaye, N. Khutoryansky, et al.
Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
Diabetes Med, 21 (2004), pp. 329-335
[48.]
N.J. Furlong, S.A. Hulme, S.V. O’Brien, K.J. Hardy.
Comparison of repaniglide vs gliclazide in combination with bedtime NPH insulin in patients with type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
Diabet Med, 20 (2003), pp. 935-941
Copyright © 2008. Sociedad Española de Endocrinología y Nutrición
